285 active trials 156 recruiting 55 Phase 3 155 sponsors 47 changes in 30 days
| Early Phase 1 | 4 | |
| Phase 1 | 18 | |
| Phase 1/2 | 28 | |
| Phase 2 | 108 | |
| Phase 2/3 | 6 | |
| Phase 3 | 49 | |
| Phase 4 | 5 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT06217185 | The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment… | Hebei Medical University Fourth Hospital | Recruiting | 2024-02-28 |
| NCT07768358 | Tucatinib Continuation Study | Pfizer | Not Yet Recruiting | 2026-08-28 |
| NCT07589699 | Trastuzumab Rezetecan (T-DXh) in HER2+ Breast Cancer With Non-pCR After TCbHP | The First Affiliated Hospital with Nanjing Medical University | Not Yet Recruiting | 2026-05-15 |
| NCT06868017 | Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with… | The First Hospital of Jilin University | Not Yet Recruiting | 2025-03-10 |
| NCT06818773 | Inetetamab Plus Chemotherapy ± PD-1/PD-L1 in HER2+ Advanced Biliary Cancer | Eastern Hepatobiliary Surgery Hospital | Not Yet Recruiting | 2025-02-10 |
| Phase 3 | ||||
| NCT06764875 | A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab… | AstraZeneca | Recruiting | 2026-09-11 |
| NCT06876714 | ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+… | Alliance for Clinical Trials in Oncology | Recruiting | 2026-09-02 |
| NCT07543536 | Megestrol Acetate for Fatigue Management in T-DXd Treated Breast Cancer | Sun Yat-sen University | Recruiting | 2026-08-14 |
| NCT07673029 | A Trial Comparing GQ1005 and T-DM1 in Patients With HER2-Positive Unresectable or… | GeneQuantum Healthcare (Suzhou) Co., Ltd. | Recruiting | 2026-06-29 |
| NCT07518173 | A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and… | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | 2026-06-04 |
| NCT07047365 | TQB2930 Injection for the Treatment of HER2-positive Advanced Breast Cancer | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | 2026-06-03 |
| NCT07441460 | A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable… | Shanghai JMT-Bio Inc. | Recruiting | 2026-04-08 |
| NCT07043725 | A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal… | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Recruiting | 2026-03-27 |
| NCT06532006 | A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for… | Shanghai Henlius Biotech | Recruiting | 2026-02-27 |
| NCT07377643 | IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in… | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Recruiting | 2026-02-25 |
| NCT06435429 | A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in… | Jazz Pharmaceuticals | Recruiting | 2026-02-10 |
| NCT06830889 | A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer… | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | 2026-01-22 |
| NCT05760612 | Adjuvant Trastuzumab Plus Neratinib in Hormone Receptor-Positive/Human Epidermal Growth… | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | 2025-09-25 |
| NCT06992882 | A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral… | Fudan University | Recruiting | 2025-07-18 |
| NCT07062263 | Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced… | Tata Memorial Centre | Recruiting | 2025-07-14 |
| NCT05838066 | Efficacy and Safety of KN026 in Combination With HB1801 in the First-line Treatment of… | Shanghai JMT-Bio Inc. | Recruiting | 2025-05-30 |
| NCT01785420 | Pre Operative Trastuzumab in Operable Breast Cancer | Dr Rajendra A. Badwe | Recruiting | 2025-04-09 |
| NCT06846437 | JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer | Shanghai JMT-Bio Inc. | Recruiting | 2025-03-24 |
| NCT04547907 | A Comparison of Nab-PHP and TCbHP Efficacy in Neoadjuvant Therapy for HER2-positive Early… | Henan Cancer Hospital | Recruiting | 2024-09-20 |
| NCT06313086 | DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast… | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Recruiting | 2024-05-10 |
Fudan University (11) · Shanghai JMT-Bio Inc. (8) · Shu Wang (7) · Sichuan Baili Pharmaceutical Co., Ltd. (7) · Henan Cancer Hospital (6) · Memorial Sloan Kettering Cancer Center (6) · Dana-Farber Cancer Institute (5) · H. Lee Moffitt Cancer Center and Research Institute (5) · Jiangsu HengRui Medicine Co., Ltd. (5) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (5)